Reduced von Willebrand factor survival in type Vicenza von Willebrand disease

• Published in: Blood 2002-01, Vol.99 (1), p.180-184
• Main Authors: Casonato, Alessandra, Pontara, Elena, Sartorello, Francesca, Cattini, Maria Grazia, Sartori, Maria Teresa, Padrini, Roberto, Girolami, Antonio
• Format: Article
• Language: English
• Subjects: Biological and medical sciences; Blood Platelets - chemistry; Deamino Arginine Vasopressin - pharmacology; DNA Mutational Analysis; Drug Stability; Factor VIII - analysis; Half-Life; Hematologic and hematopoietic diseases; Humans; Italy; Kinetics; Macromolecular Substances; Medical sciences; Mutation; Platelet Aggregation - drug effects; Platelet diseases and coagulopathies; Ristocetin - pharmacology; von Willebrand Diseases - blood; von Willebrand Diseases - genetics; von Willebrand Factor - analysis; von Willebrand Factor - chemistry; von Willebrand Factor - genetics; von Willebrand Factor - metabolism
• ISSN: 0006-4971; 1528-0020
• DOI: 10.1182/blood.V99.1.180

Type Vicenza variant of von Willebrand disease (VWD) is characterized by a low plasma von Willebrand factor (VWF) level and supranormal VWF multimers. Two candidate mutations, G2470A and G3864A at exons 17 and 27, respectively, of the VWF gene were recently reported to be present in this disorder. Four additional families, originating from northeast Italy, with both mutations of type Vicenza VWD are now described. Like the original type Vicenza subjects, they showed a mild bleeding tendency and a significant decrease in plasma VWF antigen level and ristocetin cofactor activity but normal platelet VWF content. Unlike the original patients, ristocetin-induced platelet aggregation was found to be normal. Larger than normal VWF multimers were also demonstrated in the plasma. Desmopressin (DDAVP) administration increased factor VIII (FVIII) and VWF plasma levels, with the appearance of even larger multimers. However, these forms, and all VWF oligomers, disappeared rapidly from the circulation. The half-life of VWF antigen release and of elimination was significantly shorter than that in healthy counterparts, so that at 4 hours after DDAVP administration, VWF antigen levels were close to baseline. Similar behavior was demonstrated by VWF ristocetin cofactor activity and FVIII. According to these findings, it is presumed that the low plasma VWF levels of type Vicenza VWD are mainly attributed to reduced survival of the VWF molecule, which, on the other hand, is normally synthesized. In addition, because normal VWF-platelet GPIb interaction was observed before or after DDAVP administration, it is proposed that type Vicenza VWD not be considered a 2M subtype.